BioLineRX Ltd.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BioLineRx Ltd. (NASDAQ/TASE: BLRX) develops and commercializes innovative therapeutics for oncology and rare diseases; the company focuses on advancing novel drug candidates through clinical development, leveraging expertise in stem cell mobilization, immuno-oncology, and targeted cancer therapies. Founded in 2003 and headquartered at 2 HaMa’ayan Street, Modi’in Technology Park, Hevel Modi’in, Israel, BioLineRx operates primarily in the United States and Israel, with strategic partnerships extending development and commercialization rights into Asia and other global territories. The company's lead product, APHEXDA (motixafortide), a high-affinity CXCR4 peptide inhibitor, is FDA-approved for stem cell mobilization in combination with filgrastim (G-CSF) for autologous transplantation in multiple myeloma patients; motixafortide is also in Phase 2b trials for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) in combination with cemiplimab and chemotherapy (CheMo-4-METPANC study sponsored by Columbia University), Phase 1 trials for sickle cell disease stem cell mobilization (collaborations with Washington University and St. Jude Children’s Research Hospital), and subject to bridging studies for multiple myeloma in China. BioLineRx's pipeline emphasizes motixafortide's broad applicability across hematopoietic stem cell mobilization, solid tumors, and rare hematologic disorders, targeting unmet needs in cancer stem cell therapy and immune cell recruitment. In November 2024, BioLineRx entered an exclusive licensing agreement with Ayrmid Ltd. (parent of Gamida Cell) granting Ayrmid global rights (excluding Asia and solid tumors) to develop and commercialize APHEXDA, providing $10 million upfront, up to $87 million in milestones, 18-23% royalties, and a $9 million equity investment from Highbridge Capital Management, alongside significant cash burn reduction to extend runway into 2026; in October 2023, BioLineRx partnered with Guangzhou Gloria Biosciences for Asian rights to motixafortide across indications, including $15 million upfront, up to $250 million in milestones, and a $14.6 million equity investment, with GloriaBio advancing PDAC and multiple myeloma bridging studies in China and Japan. These non-dilutive deals support BioLineRx's transition to a lean development model, funding pipeline progression while generating initial APHEXDA revenues of $7.9 million in Q3 2024.
Company News
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call Transcript
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
BioLineRx (BLRX) Projected to Post Quarterly Earnings on Monday
Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings